Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy
Status:
Completed
Trial end date:
2017-02-14
Target enrollment:
Participant gender:
Summary
The study aims to assess the safety and efficacy of darunavir 800mg plus the co-formulated
elvitegravir/cobicistat/tenofovir disoproxil fumarate (DF)/emtricitabine (Stribild) tablet as
a simplification strategy for the treatment of HIV infection in HIV-infected subjects who
have had previous antiretroviral treatment experience with multiple-drug regimens.
We hypothesize that elvitegravir/cobicistat/tenofovir DF/emtricitabine with darunavir will
offer a safe and efficacious treatment simplification strategy for HIV positive patients
currently receiving multiple-drug regimens to control their HIV infection.